Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Apogee Therapeutics, Inc. - Common Stock (NQ:APGE)

41.96 +0.78 (+1.89%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 20, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 637,498
Open 41.45
Bid (Size) 41.95 (5)
Ask (Size) 42.08 (6)
Prev. Close 41.18
Today's Range 40.33 - 42.66
52wk Range 26.20 - 63.50
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Apogee Therapeutics to Participate at the Jefferies Global Healthcare Conference
From Apogee Therapeutics
Via GlobeNewswire
Why Is Apogee Therapeutics Stock Trading Higher On Monday?
Apogee's APG808 cut key asthma biomarker FeNO by 53% at 12 weeks with no severe adverse events, showing potential for long-term maintenance dosing. 
Via Benzinga

Performance

YTD
-11.0%
-11.0%
1 Month
+4.4%
+4.4%
3 Month
+5.3%
+5.3%
6 Month
-12.1%
-12.1%
1 Year
+10.3%
+10.3%

More News

Read More
Apogee Therapeutics Provides Business Update, Pipeline Progress and Reports First Quarter 2025 Financial Results
From Apogee Therapeutics
Via GlobeNewswire
Apogee Therapeutics Announces Positive Interim Results from the Phase 1b Trial of APG808, its Novel Half-life Extended IL-4Rα Antibody, in Patients with Mild-to-Moderate Asthma
From Apogee Therapeutics
Via GlobeNewswire
Apogee Therapeutics to Participate at the Bank of America 2025 Health Care Conference
From Apogee Therapeutics
Via GlobeNewswire
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
Apogee Therapeutics' Investigational Atopic Dermatitis Potential Shows Strong Tolerability, Extended Half-Life in Early Trial
Via Benzinga
Apogee Therapeutics Provides Pipeline Progress and Reports Full Year 2024 Financial Results
From Apogee Therapeutics
Via GlobeNewswire
Apogee Therapeutics Announces Positive Interim Phase 1 Results from the APG990 Healthy Volunteer Trial, Unlocking Potential Maintenance Dosing Every Three and Six Months for APG279 (APG777 + APG990)
From Apogee Therapeutics
Via GlobeNewswire
Apogee Therapeutics to Host Conference Call to Report Interim Results from the Phase 1 Healthy Volunteer Trial for APG990 and Provide Combination Strategy Update on March 3, 2025
From Apogee Therapeutics
Via GlobeNewswire
Apogee Therapeutics to Participate in Upcoming March Investor Conferences
From Apogee Therapeutics
Via GlobeNewswire
Why Upstart Shares Are Trading Higher By Over 25%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Apogee Therapeutics Announces First Patient Dosed in Part B of Phase 2 APEX Trial of APG777 in Patients with Moderate-to-Severe Atopic Dermatitis
From Apogee Therapeutics
Via GlobeNewswire
Apogee Therapeutics to Participate at the Guggenheim SMID Cap Biotech Conference
From Apogee Therapeutics
Via GlobeNewswire
Apogee Therapeutics Announces First Participants Dosed in Phase 1 Clinical Trial of APG333, its Novel Half-Life Extended TSLP Antibody for the Treatment of Respiratory and Broader I&I Conditions
From Apogee Therapeutics
Via GlobeNewswire
Apogee Therapeutics Highlights Progress and Best-in-Class Potential of Novel Biologic Programs for I&I Diseases at 2024 Inaugural R&D Day
From Apogee Therapeutics
Via GlobeNewswire
Apogee Therapeutics Announces Agenda for Virtual R&D Day
From Apogee Therapeutics
Via GlobeNewswire
This Sarepta Therapeutics Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Monday
Via Benzinga
Apogee Therapeutics to Host Inaugural Virtual R&D Day on December 2, 2024
From Apogee Therapeutics
Via GlobeNewswire
Apogee Therapeutics Provides Pipeline Progress and Reports Third Quarter 2024 Financial Results
From Apogee Therapeutics
Via GlobeNewswire
Apogee Therapeutics to Participate in Upcoming November Investor Conferences
From Apogee Therapeutics
Via GlobeNewswire
Apogee Therapeutics Announces Results Up to 9 Months from Phase 1 Trial of APG777, its Novel Half-Life Extended Anti-IL-13 Antibody for the Treatment for Atopic Dermatitis and Other Inflammatory Diseases
From Apogee Therapeutics
Via GlobeNewswire
Apogee Therapeutics Announces Poster Presentation at the ACAAI 2024 Annual Scientific Meeting
From Apogee Therapeutics
Via GlobeNewswire
Apogee Therapeutics to Participate at the Stifel 2024 Immunology and Inflammation Summit
From Apogee Therapeutics
Via GlobeNewswire
Apogee Therapeutics Appoints Jeff S. Hartness as Chief Commercial Officer
From Apogee Therapeutics
Via GlobeNewswire

Frequently Asked Questions

Is Apogee Therapeutics, Inc. - Common Stock publicly traded?
Yes, Apogee Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Apogee Therapeutics, Inc. - Common Stock trade on?
Apogee Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Apogee Therapeutics, Inc. - Common Stock?
The ticker symbol for Apogee Therapeutics, Inc. - Common Stock is APGE on the Nasdaq Stock Market
What is the current price of Apogee Therapeutics, Inc. - Common Stock?
The current price of Apogee Therapeutics, Inc. - Common Stock is 41.96
When was Apogee Therapeutics, Inc. - Common Stock last traded?
The last trade of Apogee Therapeutics, Inc. - Common Stock was at 06/20/25 04:00 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.